Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 62, Issue 2

Immunological evaluation of Vi capsular polysaccharide of subsp. Typhi vaccine by serum bactericidal assay No Access

Abstract

subsp. Typhi ( Typhi) Vi antigen capsular polysaccharide (Vi-CPS) is a licensed vaccine against typhoid fever. As there is no animal model for Typhi fever to evaluate the protective efficacy of the Vi-CPS vaccine, a serum bactericidal assay (SBA) is the recommended ‘gold standard’ to evaluate its potency. Vi-CPS was extracted from Typhi Ty6S (CSBPI-B191) using a modified Gotschlich method. Purified Vi-CPS (50 µg) was injected intramuscularly into three groups of five rabbits; group 2 received an additional booster dose of 50 µg Vi-CPS on day 15 and group 3 received two additional boosters on days 15 and 30. The sera obtained from each group were tested by SBA on days 0, 15, 30 and 45. The anti-Vi-CPS titres for groups 1, 2 and 3 on days 15, 30 and 45 were 4, 16 and 16; 4, 32 and 32; and 16, 64 and 64, respectively. Thus, Vi-CPS was shown to be a potent immunogen, as even one dose could induce an efficient bactericidal effect against Typhi. Although Vi-CPS is a reliable vaccine, sometimes depolymerization during purification can affect its potency, which can be resolved through a potency test. As the passive haemagglutination test recommended by the World Health Organization does not indicate vaccine potency, we recommend using an SBA to evaluate the bactericidal ability of Vi-CPS.

  • Received:
  • Accepted:
  • Published Online:
© 2013 SGM
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.047159-0
2013-02-01
2025-01-25
Loading full text...

Full text loading...

References

  1. Acharya I. L., Lowe C. U., Thapa R., Gurubacharya V. L., Shrestha M. B., Cadoz M., Schulz D., Armand J., Bryla D. A. other authors 1987; Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella Typhi. A preliminary report. N Engl J Med 317:1101–1104 [View Article][PubMed]
     [Google Scholar]
  2. Ahmadi H., Tabaraie B., Nejati M., Al-e-Agha S. 1999; Molecular characterization and optimization of Vi-capsular polysaccharide of Salmonella Typhi Ty6s production in bioreactor. Med J Islam Repub Iran 13:37–42
     [Google Scholar]
  3. Canh D. G., Lin F. Y., Thiem V. D., Trach D. D., Trong N. D., Mao N. D., Hunt S., Schneerson R., Robbins J. B. other authors 2004; Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 72:6586–6588 [View Article][PubMed]
     [Google Scholar]
  4. Chibber S., Bhardwaj S. B. 2004; Protection in a mouse peritonitis model mediated by iron-regulated outer-membrane protein of Salmonella typhi coupled to its Vi antigen. J Med Microbiol 53:705–709 [View Article][PubMed]
     [Google Scholar]
  5. Fadeel M. A., Crump J. A., Mahoney F. J., Nakhla I. A., Mansour A. M., Reyad B., El Melegi D., Sultan Y., Mintz E. D., Bibb W. F. 2004; Rapid diagnosis of typhoid fever by enzyme-linked immunosorbent assay detection of Salmonella serotype Typhi antigens in urine. Am J Trop Med Hyg 70:323–328[PubMed]
     [Google Scholar]
  6. Frantz I. D. 1942; Growth requirements of the Meningococcus . J Bacteriol 43:757–761[PubMed]
     [Google Scholar]
  7. Gotschlich E. C. 1975; Development of polysaccharide vaccines for the prevention of meningococcal diseases. Monogr Allergy 9:245–258[PubMed]
     [Google Scholar]
  8. Hestrin S. 1949; The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem 180:249–261[PubMed]
     [Google Scholar]
  9. Holst J., Feiring B., Fuglesang J. E., Høiby E. A., Nøkleby H., Aaberge I. S., Rosenqvist E. 2003; Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21:734–737 [View Article][PubMed]
     [Google Scholar]
  10. Hudson L., Hay F. 1989 Practical Immunology, 3rd edn. Oxford: Blackwell Scientific Publishers;
     [Google Scholar]
  11. Kasi A. M. 1964; Physical and chemical studies of two dried inactivated typhoid vaccines (Vaccines K and L). Bull World Health Organ 30:647–652[PubMed]
     [Google Scholar]
  12. Kim Y.-R., Yoo J. H., Hur J. K., Kang J. H., Shin W. S., Kang M. W. 1995; Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea. J Korean Med Sci 10:314–317[PubMed] [CrossRef]
     [Google Scholar]
  13. Klugman K., Koornhof H. J., Schneerson R., Cadoz M., Gilbertson I. T., Robbins J. B., Schulz D., Armand J. 1987; Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet U 330:1165–1169 [View Article]
     [Google Scholar]
  14. Klugman K. P., Koornhof H. J., Robbins J. B., Le Cam N. N. 1996; Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14:435–438 [View Article][PubMed]
     [Google Scholar]
  15. Lim S. M., Jung H.-S., Kim M. J., Park D.-W., Kim W.-J., Cheong H.-J., Park S.-C., Lee K.-C., Shin Y.- K. other authors 2007; Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea. J Microbiol Biotechnol 17:611–615[PubMed]
     [Google Scholar]
  16. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. 1951; Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275[PubMed]
     [Google Scholar]
  17. Maslanka S. E., Gheesling L. L., Libutti D. E., Donaldson K. B., Harakeh H. S., Dykes J. K., Arhin F. F., Devi S. J., Frasch C. E. other authors 1997; Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 4:156–167[PubMed]
     [Google Scholar]
  18. Mastroeni P., Ménager N. 2003; Development of acquired immunity to Salmonella . J Med Microbiol 52:453–459 [View Article][PubMed]
     [Google Scholar]
  19. Nolan C. M., Feeley J. C., White P. C. Jr, Hambie E. A., Brown S. L., Wong K.-H. 1980; Evaluation of a new assay for Vi antibody in chronic carriers of Salmonella typhi . J Clin Microbiol 12:22–26[PubMed]
     [Google Scholar]
  20. Rodríguez T., Lastre M., Cedré B., del Campo J., Bracho G., Zayas C., Taboada C., Díaz M., Sierra G., Pérez O. 2002; Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay. Clin Diagn Lab Immunol 9:109–114[PubMed]
     [Google Scholar]
  21. Szu S. C., Li X.-R., Stone A. L., Robbins J. B. 1991; Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect Immun 59:4555–4561[PubMed]
     [Google Scholar]
  22. Szu S. C., Taylor D. N., Trofa A. C., Clements J. D., Shiloach J., Sadoff J. C., Bryla D. A., Robbins J. B. 1994; Laboratory and preliminary clinical characterization of Vi capsular polysaccharide–protein conjugate vaccines. Infect Immun 62:4440–4444[PubMed]
     [Google Scholar]
  23. Tang S.-S., Tan W.-S., Devi S., Wang L.-F., Pang T., Thong K.-L. 2003; Mimotopes of the Vi antigen of Salmonella enterica serovar Typhi identified from phage display peptide library. Clin Diagn Lab Immunol 10:1078–1084[PubMed]
     [Google Scholar]
  24. Wain J., House D., Zafar A., Baker S., Nair S., Kidgell C., Bhutta Z., Dougan G., Hasan R. 2005; Vi antigen expression in Salmonella enterica serovar Typhi clinical isolates from Pakistan. J Clin Microbiol 43:1158–1165 [View Article][PubMed]
     [Google Scholar]
  25. WHO 1973; General Requirements for the Sterility of Biological Substances; 25th report. WHO Technical Report Series, No. 530. Geneva: World Health Organization; Annex 4
    [Google Scholar]
  26. WHO 1974; Requirements for Vi-polysaccharide Typhoid Vaccine. WHO Technical Report. Series, No. 840. Geneva: World Health Organization; Annex 1
    [Google Scholar]
  27. WHO 1976; Requirements for Meningococcal Polysaccharide Vaccine; 27th report. WHO Technical Report Series, No. 594. Geneva: World Health Organization; Annex 2
    [Google Scholar]
  28. WHO 1979; The International Pharmacopoeia, 3rd edn, Vol. 1. General Methods of Analysis . Geneva: World Health Organization;
     [Google Scholar]
  29. WHO 1981; Requirements for meningococcal polysaccharide vaccine (Requirements for biological substances no. 23, addendum 1980). In: WHO Expert Committee on Biological Standardization 31st report. WHO Technical Report Series, No. 658. Geneva: World Health Organization. Annex 6
    [Google Scholar]
  30. WHO 1994; Requirements for Vi Polysaccharide Typhoid Vaccine. WHO Technical Report Series, No. 840. Geneva: World Health Organization; Annex 1
    [Google Scholar]
  31. Yang H. H., Wu C. G., Xie G. Z., Gu Q. W., Wang B. R., Wang L. Y., Wang H. F., Ding Z. S., Yang Y. other authors 2001; Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 79:625–631[PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.047159-0
Loading
Immunological evaluation of Vi capsular polysaccharide of Salmonella enterica subsp. Typhi vaccine by serum bactericidal assay
J. Med. Microbiol. 62, 283 (2013); https://doi.org/10.1099/jmm.0.047159-0
/content/journal/jmm/10.1099/jmm.0.047159-0
/content/journal/jmm/10.1099/jmm.0.047159-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error